시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 전장 유전체 및 엑솜 시퀀싱 시장 보고서(2025년)
Whole Genome And Exome Sequencing Global Market Report 2025
상품코드 : 1825586
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,625,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,576,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,527,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

전장 유전체 및 엑솜 시퀀싱 시장 규모는 앞으로 수년간 비약적인 성장이 예상됩니다. 2029년에 CAGR은 24.8%를 나타낼 것으로 예측되고 61억 1,000만 달러로 성장할 전망입니다. 예측 기간 동안의 성장은 인구 유전체학 이니셔티브, 정밀 의학에 대한 수요 증가, 단일 세포 시퀀싱 기술 발전, 비침습적 산전 검사(NIPT) 확대, 희귀 질환 연구 용도 등에 기인할 수 있습니다. 예측 기간의 주요 동향으로는 임상 적용 확대, 시퀀싱 기술의 급속한 발전, 인구 규모 유전체 연구의 부상, 인공지능(AI) 및 머신 러닝(ML) 통합, 종양학 분야에서의 응용 확대 등이 있습니다.

향후 5년간 24.8% 성장 전망은 이전 예측 대비 0.1% 소폭 하락한 수치입니다. 이 하락은 주로 미국과 타국 간 관세 영향 때문입니다. 관세 장벽은 한국과 스위스에서 공급원되는 고처리량 DNA 시퀀서 및 생물정보학 소프트웨어의 비용을 증가시켜 미국 내 희귀질환 진단 지연과 유전체 의학 프로그램 비용 상승을 초래할 것으로 예상됩니다. 또한 상호 관세 부과와 무역 긴장 및 제한 강화로 인한 전 세계 경제 및 무역에 대한 부정적 영향으로 그 효과가 더욱 광범위하게 나타날 것입니다.

맞춤형 의약품에 대한 관심이 증가함에 따라 향후 몇 년간 전장 유전체 및 엑솜 시퀀싱 시장이 확대될 것으로 촉진될 것으로 예상됩니다. 맞춤형 의약품은 유전적 특성, 환경, 생활습관 등 개별 환자의 특성을 고려하여 치료 결정을 내리는 맞춤형 접근법을 채택합니다. 전장 유전체 및 엑솜 시퀀싱은 개인의 유전적 구성을 종합적으로 분석하여 특정 유전적, 환경적, 생활습관적 요인에 맞춤화된 의료 개입을 가능케 함으로써 맞춤형 의학에서 중추적 역할을 수행합니다. 예를 들어, 2022년 10월 시점에서 맞춤형 의료연합(PMC)은 75,000개 이상의 유전자 검사 제품과 300개 이상의 개별화 의약품이 시장에 나설 것으로 예측했습니다. 또한 미국 식품의약국(FDA)의 의약품평가연구센터(CDER)는 2022년 37개의 신규분자화합물(NME)을 승인했으며, 35개의 치료용 NME 중 약 34%가 개별화약으로 분류됩니다. 결과적으로 맞춤형 의약품에 대한 수요 증가는 전장 유전체 및 엑솜 시퀀싱 시장 확장을 촉진하고 있습니다

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

HBR
영문 목차

영문목차

Whole genome sequencing (WGS) and exome sequencing (ES) are advanced genetic analysis methodologies aimed at deciphering an organism's complete DNA sequence and specifically targeting the protein-coding regions of the genome. These techniques play a crucial role in diagnosing genetic disorders and identifying cancer-related mutations.

The primary product categories in WGS and ES comprise kits and instruments, where kits encompass a collection of related products packaged together for simplified inventory management. Various workflows such as whole genome sequencing (WGS) and whole exome sequencing (WES) are utilized across multiple applications including diagnostics, cancer research, monogenic disorders, drug development, personalized medicine, agriculture, and animal research. End users encompass diverse entities such as research centers, academic institutions, governmental bodies, hospitals, pharmaceutical and biotechnology companies, among others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The whole genome and exome sequencing market research report is one of a series of new reports from The Business Research Company that provides whole genome and exome sequencing market statistics, including whole genome and exome sequencing industry global market size, regional shares, competitors with a whole genome and exome sequencing market share, detailed whole genome and exome sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the whole genome and exome sequencing industry. This whole genome and exome sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The whole genome and exome sequencing market size has grown exponentially in recent years. It will grow from $2.02 billion in 2024 to $2.52 billion in 2025 at a compound annual growth rate (CAGR) of 24.5%. The growth in the historic period can be attributed to decreasing sequencing costs, rise in genetic disorders, clinical applications, genomic data repositories, advancements in bioinformatics.

The whole genome and exome sequencing market size is expected to see exponential growth in the next few years. It will grow to $6.11 billion in 2029 at a compound annual growth rate (CAGR) of 24.8%. The growth in the forecast period can be attributed to population genomics initiatives, rising demand for precision medicine, advancements in single-cell sequencing, expansion of non-invasive prenatal testing (NIPT), application in rare disease research. Major trends in the forecast period include expanded clinical adoption, rapid advancements in sequencing technologies, rise of population-scale genomic studies, integration of artificial intelligence (AI) and machine learning (ML), expanding applications in oncology.

The forecast of 24.8% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S.by increasing the cost of high-throughput Deoxyribonucleic acid sequencers and bioinformatics software sourced from South Korea and Switzerland, thereby delaying rare disease diagnoses and elevating genomic medicine program costs The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing interest in personalized medicine is anticipated to drive the expansion of the whole genome and exome sequencing market in the coming years. Personalized medicine adopts a tailored approach to healthcare, considering individual patient characteristics such as genetics, environment, and lifestyle in treatment decisions. Whole genome and exome sequencing play a pivotal role in personalized medicine by offering a comprehensive analysis of an individual's genetic composition, enabling healthcare interventions customized to their specific genetic, environmental, and lifestyle factors. For example, as of October 2022, the Personalized Medicine Coalition (PMC) projects over 75,000 genetic testing products and 300 personalized medicines to be available on the market. Additionally, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs) in 2022, with approximately 34% classified as personalized among the 35 therapeutic NMEs. Consequently, the growing demand for personalized medicine is fueling the expansion of the whole genome and exome sequencing market.

Major players in the whole genome and exome sequencing markets are intensifying their efforts towards developing cutting-edge technological solutions, notably ultra-fast NGS (next-generation sequencing) analysis, to gain a competitive advantage. This innovation facilitates the rapid processing of NGS data, drastically reducing analysis time. For example, in January 2023, QIAGEN Digital Insights (QDI), a US-based bioinformatics company, introduced an ultra-fast NGS analysis platform. This platform boasts features such as processing a whole genome in just 25 minutes at a cost of $1 in cloud computing expenses, promoting efficiency, affordability, and scalability. Its technological breakthrough significantly enhances the speed and accessibility of genomic data analysis, playing a crucial role in the whole genome and exome sequencing market by enabling swift decision-making and wider adoption of personalized medicine.

In January 2023, QIAGEN, a multinational corporation headquartered in Germany and specializing in sample technologies and molecular insights products, acquired Verogen for an undisclosed sum. This acquisition bolsters QIAGEN's presence in the human identification and forensics market, consolidating its leadership position and facilitating the creation of more comprehensive solutions with potential implications for the entire genome and exome sequencing market. Verogen, based in the United States, is a biotech company that offers next-generation sequencing (NGS) tools and services, including whole genome and exome sequencing.

Major companies operating in the whole genome and exome sequencing market report are Siemens AG, Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Cytiva (Danaher Corporation), Laboratory Corporation of America Holdings (Labcorp), Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Canon Medical Systems Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V, Neusoft Corporation, BGI Genomics, Mirion Technologies (Capintec) Inc., Novogene Co., Oxford Nanopore Technologies Inc., LANDAUER, Pacific Biosciences of California Inc., Digirad Corporation, Berthold Technologies GmbH & Co.KG, GENEWIZ Inc., Incom Inc., Lucerno Dynamics LLC, Absolute Imaging Inc., Mediso Ltd., Ashby Gorman Baker Ltd., DDD-Diagnostic AS, SurgicEye GmbH, CMR Naviscan

North America was the largest region in the whole genome and exome sequencing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the whole genome and exome sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the whole genome and exome sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The whole genome and exome sequencing market consists of revenues earned by entities by providing services such as genetic profiling, variant identification, personalized medicine solutions, and comprehensive genomic analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The whole genome and exome sequencing market also includes sales of exome capture kits, benchtop sequencer, and sample preparation instrutments. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Whole Genome And Exome Sequencing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on whole genome and exome sequencing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for whole genome and exome sequencing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The whole genome and exome sequencing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Whole Genome And Exome Sequencing Market Characteristics

3. Whole Genome And Exome Sequencing Market Trends And Strategies

4. Whole Genome And Exome Sequencing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Whole Genome And Exome Sequencing Growth Analysis And Strategic Analysis Framework

6. Whole Genome And Exome Sequencing Market Segmentation

7. Whole Genome And Exome Sequencing Market Regional And Country Analysis

8. Asia-Pacific Whole Genome And Exome Sequencing Market

9. China Whole Genome And Exome Sequencing Market

10. India Whole Genome And Exome Sequencing Market

11. Japan Whole Genome And Exome Sequencing Market

12. Australia Whole Genome And Exome Sequencing Market

13. Indonesia Whole Genome And Exome Sequencing Market

14. South Korea Whole Genome And Exome Sequencing Market

15. Western Europe Whole Genome And Exome Sequencing Market

16. UK Whole Genome And Exome Sequencing Market

17. Germany Whole Genome And Exome Sequencing Market

18. France Whole Genome And Exome Sequencing Market

19. Italy Whole Genome And Exome Sequencing Market

20. Spain Whole Genome And Exome Sequencing Market

21. Eastern Europe Whole Genome And Exome Sequencing Market

22. Russia Whole Genome And Exome Sequencing Market

23. North America Whole Genome And Exome Sequencing Market

24. USA Whole Genome And Exome Sequencing Market

25. Canada Whole Genome And Exome Sequencing Market

26. South America Whole Genome And Exome Sequencing Market

27. Brazil Whole Genome And Exome Sequencing Market

28. Middle East Whole Genome And Exome Sequencing Market

29. Africa Whole Genome And Exome Sequencing Market

30. Whole Genome And Exome Sequencing Market Competitive Landscape And Company Profiles

31. Whole Genome And Exome Sequencing Market Other Major And Innovative Companies

32. Global Whole Genome And Exome Sequencing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Whole Genome And Exome Sequencing Market

34. Recent Developments In The Whole Genome And Exome Sequencing Market

35. Whole Genome And Exome Sequencing Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기